LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Pfizer

Pfizer

Gesloten

SectorGezondheidszorg

25.9 0.04

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.9

Max

Belangrijke statistieken
By Trading Economics
Inkomsten	4.3B 2.7B
Verkoop	-3.1B 14B
K/W Sectorgemiddelde	19.336 49.701
EPS	0.75
Dividendrendement	6.79
Winstmarge	18.656
Werknemers	75,000
EBITDA	4.5B 5.2B

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+12.63% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	6.79% 2.39%
Volgende Winsten	4 aug 2026
Volgende dividenddatum	12 jun 2026
Volgende Ex Dividend datum	24 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-5.2B 144B
Vorige openingsprijs	25.86
Vorige sluitingsprijs	25.9

Nieuwssentiment

By Acuity

33%

67%

91 / 345 Rangschikking in Healthcare

Pfizer Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mei 2026, 11:31 UTC

Winsten

Pfizer 1Q Revenue Rises But Profit Falls Amid Boosted R&D Spending

5 mei 2026, 18:12 UTC

Winsten

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mei 2026, 13:54 UTC

Winsten

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mei 2026, 12:35 UTC

Winsten

Pfizer Posts Better-Than-Expected Revenue, Profit -- WSJ

5 mei 2026, 11:06 UTC

Winsten

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates -- Barrons.com

5 mei 2026, 10:47 UTC

Winsten

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

5 mei 2026, 10:47 UTC

Winsten

Pfizer Still Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

5 mei 2026, 10:46 UTC

Winsten

Pfizer 1Q Revenue of Launched, Acquired Products Rose 22% Operationally >PFE

5 mei 2026, 10:46 UTC

Winsten

Pfizer 1Q Revenue Rose 7% Operationally Excluding Contributions From Comirnaty, Paxlovid >PFE

5 mei 2026, 10:45 UTC

Winsten

Pfizer Reaffirms 2026 Guidance >PFE

5 mei 2026, 10:45 UTC

Winsten

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

5 mei 2026, 10:45 UTC

Winsten

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

5 mei 2026, 10:45 UTC

Winsten

Pfizer 1Q Rev $14.5B >PFE

5 mei 2026, 10:45 UTC

Winsten

Pfizer 1Q EPS 47c >PFE

5 mei 2026, 10:45 UTC

Winsten

Pfizer 1Q Net $2.69B >PFE

5 mei 2026, 10:45 UTC

Winsten

Pfizer 1Q Adj EPS 75c >PFE

5 mei 2026, 10:36 UTC

Populaire aandelen

Stocks to Watch: Palantir, HSBC, Intel, AMD -- WSJ

23 apr 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

1 apr 2026, 20:07 UTC

Acquisities, Fusies, Overnames

Why 2026 Is Biotech's Comeback Year -- Barrons.com

11 mrt 2026, 11:02 UTC

Marktinformatie

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

10 mrt 2026, 12:50 UTC

Winsten

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

10 mrt 2026, 11:18 UTC

Winsten

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

9 mrt 2026, 09:43 UTC

Populaire aandelen

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

10 feb 2026, 21:51 UTC

Winsten

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:17 UTC

Winsten

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

3 feb 2026, 21:36 UTC

Winsten

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 feb 2026, 19:56 UTC

Winsten

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 19:46 UTC

Winsten

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 feb 2026, 17:35 UTC

Winsten

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 17:30 UTC

Winsten

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Pfizer Prognose

Koersdoel

By TipRanks

12.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.17 USD 12.63%

Hoogste 36 USD

Laagste 25 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pfizer - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

22 ratings

Buy

Hold

Sell

Gebaseerd op 22 analisten die aandelenratings hebben gegeven aan Pfizer - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

91 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.